| Typicality: | 0.425 |
| Saliency: | 0.410 |
| currently | 16 | temporal |
| for psoriasis | 6 | transitive-object |
| to target amyloid plaques | 2 | purpose |
| antibody → be in → phase 1 clinical trials | 9 |
| antibody → be in → clinical trials | 7 |
| antibody → be tested in → clinical trials | 6 |
| antibody → be evaluated in → clinical trials | 3 |
| negative | neutral | positive |
| 0.112 | 0.640 | 0.248 |
| Raw frequency | 25 |
| Normalized frequency | 0.410 |
| Modifier score | 0.500 |
| Perplexity | 97.222 |